Unlocking the Multi-Omics Potential of a Blood Spot - Report - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Unlocking the Multi-Omics Potential of a Blood Spot

  • By

  • Jessica Allerton

  • November 20, 2026

  • 5 min

Share

Clinical Report: Unlocking the Multi-Omics Potential of a Blood Spot

Overview

Timothy Garrett and Esabella Powers describe a protocol for extracting metabolites and lipids from one 10 µL dried blood spot (DBS) for analysis by liquid chromatography–high-resolution tandem mass spectrometry (LC-HRMS/MS). The approach addresses the limited sample volume and differing chemical properties of the two molecular classes, but further development and clinical validation are needed to assess its potential for broader newborn screening and diagnostic use.

Background

DBS are used in newborn screening to identify conditions, including inborn errors of metabolism, through measurement of specific metabolites. Their low-volume collection and practical storage and transport have also supported research across multiple molecular classes. However, most DBS workflows analyze one molecular class at a time, limiting the biochemical information obtained from a small or irreplaceable specimen. Measuring metabolites and lipids from the same spot is intended to broaden the profile available for research.

Data Highlights

AspectReported details
SampleSingle 10 µL volumetric DBS
ExtractionBiphasic extraction modeled on the Folch method; lipids partition into the organic phase and metabolites into the aqueous phase
AnalysisLC-HRMS/MS; metabolite processing in MZmine and lipid annotation using LipidMatch
Reliability assessmentMultiple extractions from the same donors on different days were compared
Pre-analytical considerationsSpecimen matrix, drying and storage, hematocrit, and spot volume can affect measured profiles

Key Findings

  • The protocol extracts metabolites and lipids from one DBS, enabling both molecular classes to be analyzed from the same sample.
  • A biphasic extraction was used to accommodate the different chemical properties of polar metabolites and lipids.
  • A lower reconstitution volume was used to concentrate analytes and improve signal intensity; glass pipettes and tubes were used to minimize polyethylene glycol contamination.
  • Metabolites were processed in MZmine and identified through MS/MS spectral matching and an in-house LC-MS library based on mass-to-charge ratio and retention time. Lipids were annotated with LipidMatch using data-dependent MS/MS and full-scan data.
  • Repeat extractions from the same donors on different days were analyzed using the same workflow and compared to assess reliability and reproducibility.
  • The authors report that DBS measurements may not be directly comparable with plasma or serum reference values; drying and storage, hematocrit, and spot volume are additional sources of variability. Volumetric DBS devices were used to collect a fixed 10 µL volume.

Clinical Implications

The authors state that specimen type and pre-analytical factors should be considered when interpreting DBS metabolite and lipid measurements, particularly when comparing them with plasma or serum reference values or when using non-volumetric cards. They report that clinical validation and further development are needed to assess the method’s potential for broader newborn screening and diagnostic use.

Conclusion

The described LC-HRMS/MS workflow enables metabolite and lipid profiling from a single 10 µL DBS. Its broader screening or diagnostic application remains to be assessed through further development and clinical validation.

Related Resources & Content

  1. The Analytical Scientist, 2026 — One Blood Spot, Two Omics Readouts
  2. The Analytical Scientist — One Blood Spot, Two Omics Readouts
  3. ASCO Publications — Integrating multi-omics features for blood-based multi-cancer early detection.
  4. ASCO Publications — Integrating multi-omics features for blood-based multi-cancer early detection.
  5. One Blood Spot, Two Omics Readouts
  6. HRSA Modernizes National Newborn Screening Review Process to Speed Up Evaluation of Emerging Conditions | HRSA
  7. Expanding Conditions for Newborn Screening-Findings from an Untargeted Metabolomics and Lipidomics Discovery Study.
  8. Expert consensus on the combined screening of genes and biomarkers for neonatal diseases

Original Source(s)

Related Content